<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="anthelminthic/PMC6530400/results/search/disease/results.xml">
  <result pre="et al., 2007a,b; WHO, 2016). Currently, therapeutic approaches for controlling" exact="leishmaniasis" post="comprises only five drugs: the pentavalent antimonial, amphotericin B"/>
  <result pre="μg/mLa 5.01 ± 0.12 μg/mLa, Ldo Ageratum conyzoides Treatment of" exact="sleeping sickness," post="bleeding, leprosy, infectious diseases, headaches, allergies, skin diseases and"/>
  <result pre="12.5 μg/mLa, Ldo Aristeguietia glutinosa Treatment of rheumatism, ulcers, headaches," exact="diarrhea" post="and other infectious diseases. (+)-15-hydroxy-labd-7-en-17-al 3.0 μg/mLe NT Varela"/>
  <result pre="dermatological conditions, and stomach pains, as well as malaria, fever," exact="hepatitis" post="and other infectious diseases. 1β, 2α-epoxytagitinin C NT 2.2"/>
  <result pre="evaluated against L. amazonensis in a murine model of experimental" exact="cutaneous leishmaniasis." post="The treatment with this oil (30 mg/kg by intralesional"/>
  <result pre="and seeds of A. annua in a murine model of" exact="visceral leishmaniasis" post="caused by L. donovani. The authors reported that besides"/>
  <result pre="seeds of A. annua in a murine model of visceral" exact="leishmaniasis" post="caused by L. donovani. The authors reported that besides"/>
  <result pre="uncinella was also shown as a potent agent against experimental" exact="visceral leishmaniasis" post="caused by L. infantum. The intraperitoneal injection of ursolic"/>
  <result pre="was also shown as a potent agent against experimental visceral" exact="leishmaniasis" post="caused by L. infantum. The intraperitoneal injection of ursolic"/>
  <result pre="cruzi. The higher SI values (as determined using human monocyte" exact="leukemia" post="THP1 cells) for trypomastigotes were found to deoxymikanolide (SI"/>
  <result pre="20, respectively. These three compounds were efficient in an experimental" exact="cutaneous leishmaniasis" post="model induced by L. amazonensis. The treatment started 15"/>
  <result pre="respectively. These three compounds were efficient in an experimental cutaneous" exact="leishmaniasis" post="model induced by L. amazonensis. The treatment started 15"/>
  <result pre="2016a). Moreover, α-bisabolol was evaluated in a murine model of" exact="visceral leishmaniasis" post="induced by L. infantum. The daily oral treatment with"/>
  <result pre="Moreover, α-bisabolol was evaluated in a murine model of visceral" exact="leishmaniasis" post="induced by L. infantum. The daily oral treatment with"/>
  <result pre="Trop. J. Pharmac. Res.16, 2169–2178. 10.4314/tjpr.v16i9.18 BlumJ.DesjeuxP.SchwartzE.BeckB.HatzC. (2004). Treatment of" exact="cutaneous leishmaniasis" post="among travellers. J. Antimicrob. Chemother.53, 158–166. 10.1093/jac/dkh05814729756 BoraK. S.SharmaA."/>
  <result pre="J. Pharmac. Res.16, 2169–2178. 10.4314/tjpr.v16i9.18 BlumJ.DesjeuxP.SchwartzE.BeckB.HatzC. (2004). Treatment of cutaneous" exact="leishmaniasis" post="among travellers. J. Antimicrob. Chemother.53, 158–166. 10.1093/jac/dkh05814729756 BoraK. S.SharmaA."/>
  <result pre="(-)-alpha-bisabolol is active against the causative agents of Old World" exact="cutaneous leishmaniasis" post="through the induction of mitochondrial-dependent apoptosis. Apoptosis21, 1071–1081. 10.1007/s10495-016-1282-x27539477"/>
  <result pre="is active against the causative agents of Old World cutaneous" exact="leishmaniasis" post="through the induction of mitochondrial-dependent apoptosis. Apoptosis21, 1071–1081. 10.1007/s10495-016-1282-x27539477"/>
  <result pre="(2015). (-)-alpha-Bisabolol, a promising oral compound for the treatment of" exact="visceral leishmaniasis." post="J. Nat. Prod.78, 1202–1207. 10.1021/np500869726076227 CortesS.AlbuquerqueA.CabralL. I.LopesL.CampinoL.CristianoM. L. (2015)."/>
  <result pre="Agents Chemother.59, 5032–5035. 10.1128/AAC.00298-1526014947 CouraJ. R. (2015). Special issue on" exact="chagas disease." post="Mem. Inst. Oswaldo Cruz110, 275–276. 10.1590/0074-027615000125993502 Da Silva FilhoA."/>
  <result pre="robusta, alleviates pain and inflammation in a model of acute" exact="gout" post="arthritis in mice. Front. Pharmacol.9:1076. 10.3389/fphar.2018.0107630319413 FeaseyN.Wansbrough-JonesM.MabeyD. C.SolomonA. W."/>
  <result pre="alleviates pain and inflammation in a model of acute gout" exact="arthritis" post="in mice. Front. Pharmacol.9:1076. 10.3389/fphar.2018.0107630319413 FeaseyN.Wansbrough-JonesM.MabeyD. C.SolomonA. W. (2010)."/>
  <result pre="E TPGS nanoparticles for the treatment of Leishmania donovani infected" exact="visceral leishmaniasis." post="Int. J. Biol. Macromol.93, 961–970. 10.1016/j.ijbiomac.2016.09.01427645930 GirardiC.FabreN.PaloqueL.RamadaniA. P.Benoit-VicalF.González-AspajoG.et al.."/>
  <result pre="extracts from plants of central argentina on sensitive and multidrug-resistant" exact="leukemia" post="cells: isolation of an active principle from gaillardia megapotamica."/>
  <result pre="F.et al. (2017). Therapeutic effect of ursolic acid in experimental" exact="visceral leishmaniasis." post="Int. J. Parasitol. Drugs Drug Resist.7, 1–11. 10.1016/j.ijpddr.2016.12.00227984757 KariotiA.SkaltsaH.KaiserM.TasdemirD."/>
  <result pre="powder and its potential usefulness in the treatment of uncomplicated" exact="cutaneous leishmaniasis" post="in humans. Rev. Soc. Bras. Med. Trop. 50, 52–60."/>
  <result pre="and its potential usefulness in the treatment of uncomplicated cutaneous" exact="leishmaniasis" post="in humans. Rev. Soc. Bras. Med. Trop. 50, 52–60."/>
  <result pre="An. Acad. Bras. Cienc.88, 2319–2330. 10.1590/0001-376520162016012027991965 ReithingerR.BrookerS.KolaczinskiJ. H. (2007a). Visceral" exact="leishmaniasis" post="in eastern Africa–current status. Trans. R. Soc. Trop. Med."/>
  <result pre="in combination with meglumine antimoniate on treatment of Leishmania major-induced" exact="cutaneous leishmaniasis" post="in BALB/c mice. Int. J. Appl. Basic Med. Res.7,"/>
  <result pre="combination with meglumine antimoniate on treatment of Leishmania major-induced cutaneous" exact="leishmaniasis" post="in BALB/c mice. Int. J. Appl. Basic Med. Res.7,"/>
  <result pre="essential oil from Artemisia absinthium L. Formulated in nanocochleates against" exact="cutaneous leishmaniasis." post="Medicines4:38. 10.3390/medicines402003828930253 TarikuY.HymeteA.HailuA.RohloffJ. (2010). Essential-oil composition, antileishmanial, and toxicity"/>
  <result pre="P.et al.. (2017). Nanoliposomal artemisinin for the treatment of murine" exact="visceral leishmaniasis." post="Int. J. Nanomedicine12, 2189–2204. 10.2147/IJN.S10654828356736 WantM. Y.IslamuddinM.ChouhanG.DasguptaA. K.ChattopadhyayA. P.AfrinF."/>
  <result pre="K.et al.. (2015). Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental" exact="visceral leishmaniasis." post="Colloids Surf. B Biointerfaces130, 215–221. 10.1016/j.colsurfb.2015.04.01325936561 collab: WHO (2013)."/>
  <result pre="to programed cell death and presents therapeutic potential in experimental" exact="cutaneous leishmaniasis." post="PLoS ONE10:e0144946. 10.1371/journal.pone.014494626674781 YamamotoE. S.CamposB. L.LaurentiM. D.LagoJ. H.Grecco SdosS.CorbettC."/>
 </snippets>
</snippetsTree>
